NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
External Expert Profile
Allan Wailoo
Latest Publications
Delivering the Triple Win: A Value-Based Approach to Pricing
Supporting the Era of Green Pharmaceuticals in the UK
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
Read more
© Mayer Tawfik/Unsplash
Payment Models for Multi-Indication Therapies
Read more
© Photology1971/Shutterstock
The Lower Drug Costs Now Act and Pharmaceutical Innovation
